In preclinical studies in various mouse models of dyslipidemia, silencing of ANGPTL3 using GalNAc-conjugated antisense oligonucleotides (ASO) significantly reduced plasma triglycerides, HDL-C, and LDL-C levels [29]. Here, ANGPTL3 is linked to metabolic syndrome.